Correlation Between ExpreS2ion Biotech and Oncopeptides

Can any of the company-specific risk be diversified away by investing in both ExpreS2ion Biotech and Oncopeptides at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining ExpreS2ion Biotech and Oncopeptides into the same portfolio, which is an essential part of the fundamental portfolio management process.

By analyzing existing cross correlation between ExpreS2ion Biotech Holding and Oncopeptides AB, you can compare the effects of market volatilities on ExpreS2ion Biotech and Oncopeptides and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in ExpreS2ion Biotech with a short position of Oncopeptides. Check out your portfolio center. Please also check ongoing floating volatility patterns of ExpreS2ion Biotech and Oncopeptides.

Diversification Opportunities for ExpreS2ion Biotech and Oncopeptides

0.46

Correlation Coefficient

ExpreS2ion Biotech  Oncopeptides

Very weak diversification

The 3 months correlation between ExpreS2ion and Oncopeptides is 0.46. Overlapping area represents the amount of risk that can be diversified away by holding ExpreS2ion Biotech Holding and Oncopeptides AB in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Oncopeptides AB and ExpreS2ion Biotech is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on ExpreS2ion Biotech Holding are associated (or correlated) with Oncopeptides. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Oncopeptides AB has no effect on the direction of ExpreS2ion Biotech i.e., ExpreS2ion Biotech and Oncopeptides go up and down completely randomly.

Pair Corralation between ExpreS2ion Biotech and Oncopeptides

Assuming the 90 days trading horizon ExpreS2ion Biotech is expected to generate 3.53 times less return on investment than Oncopeptides. But when comparing it to its historical volatility, ExpreS2ion Biotech Holding is 1.55 times less risky than Oncopeptides. It trades about 0.09 of its potential returns per unit of risk. Oncopeptides AB is currently generating about 0.21 of returns per unit of risk over similar time horizon. If you would invest  190.00  in Oncopeptides AB on May 5, 2025 and sell it today you would earn a total of  386.00  from holding Oncopeptides AB or generate 203.16% return on investment over 90 days.

Time Period	3 Months [change]
Direction	Moves Together
Strength	Weak
Accuracy	100.0%
Values	Daily Returns

ExpreS2ion Biotech Holding  vs.  Oncopeptides AB

ExpreS2ion Biotech

Risk-Adjusted Performance

OK

Compared to the overall equity markets, risk-adjusted returns on investments in ExpreS2ion Biotech Holding are ranked lower than 7 (%) of all global equities and portfolios over the last 90 days. Despite somewhat unfluctuating basic indicators, ExpreS2ion Biotech sustained solid returns over the last few months and may actually be approaching a breakup point.

Oncopeptides AB

Risk-Adjusted Performance

Solid

Compared to the overall equity markets, risk-adjusted returns on investments in Oncopeptides AB are ranked lower than 16 (%) of all global equities and portfolios over the last 90 days. In spite of comparatively uncertain basic indicators, Oncopeptides unveiled solid returns over the last few months and may actually be approaching a breakup point.

Pair Trading with ExpreS2ion Biotech and Oncopeptides

The main advantage of trading using opposite ExpreS2ion Biotech and Oncopeptides positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if ExpreS2ion Biotech position performs unexpectedly, Oncopeptides can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Oncopeptides will offset losses from the drop in Oncopeptides' long position.

The idea behind ExpreS2ion Biotech Holding and Oncopeptides AB pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.

Check out your portfolio center.

Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Portfolio Rebalancing module to analyze risk-adjusted returns against different time horizons to find asset-allocation targets.